# Atavistic chemotherapy: combinations of antibacterial, antifungal and antiprotozoal drugs in advanced cancer (Arguello clinic, status unknown)

Source: https://onco.cc/trials/nct02366884/  
OnCo record `nct02366884` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A private Mexican clinic registered a trial of mixtures of antibiotics, antifungals and anti-parasite drugs, ivermectin among them, in any advanced cancer. The registry has not been updated since 2022, shows no results, and lists a primary endpoint judged partly by looking at tumours.

## Summary

The study is registered by a private clinic as a phase 2 with an estimated 250 participants, started in July 2011, an estimated primary completion of December 2022 and an overall status of unknown since its last update in April 2022 (ClinicalTrials.gov NCT02366884). The antiprotozoal arm lists nitazoxanide, chloroquine, albendazole, ivermectin, mebendazole, metronidazole, praziquantel and levamisole, so any result could not be attributed to ivermectin alone (ClinicalTrials.gov NCT02366884). The primary outcome is objective clinical tumour regression at six months, with methods that include changes in signs and symptoms and visual inspection of tumours alongside imaging (ClinicalTrials.gov NCT02366884). No results are posted and the registry's reference list contains only the investigator's own animal papers from 1988 to 1998 (ClinicalTrials.gov NCT02366884).

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-09-24
- Registry id: NCT02366884
- Phase: 2
- Setting: Advanced, metastatic or otherwise incurable cancers of any type after conventional treatment failed or was refused: randomised, single-blind, response-adaptive; four arms of two or six marketed anti-infective drugs, with ivermectin one of eight antiprotozoals in one arm
- Sponsor: Dr. Frank Arguello Cancer Clinic, San José del Cabo, Mexico
- Enrolled: 250
- Result: No results posted; status unknown since April 2022 (ClinicalTrials.gov NCT02366884).

## Sources

- ClinicalTrials.gov NCT02366884: https://clinicaltrials.gov/study/NCT02366884

## Connected records

- technologies: [Fenbendazole, ivermectin and other internet 'repurposed cures'](https://onco.cc/technologies/fenbendazole-ivermectin-repurposing-claims/)
- drugs: [Ivermectin](https://onco.cc/drugs/ivermectin/), [Mebendazole](https://onco.cc/drugs/mebendazole/)
- bottlenecks: [Misinformation and unproven therapies](https://onco.cc/bottlenecks/b-misinformation/)

---
JSON: https://onco.cc/api/v1/entities/nct02366884.json